ORGANIZATION

FPMAJ Demands Better Criteria for Selecting Comparator Drugs to Factor in Disease Features and Product Positioning

June 12, 2023

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Federation of Pharmaceutical Manufacturers’ Associations of Japan’s (FPMAJ) drug pricing committee spoke of the challenges in the current pricing mechanism of innovative drugs and proposed countermeasures at a press conference on June 9. The trade group pointed out that…

To read the full story

Tide Has Changed, but That Doesn’t Erase Concerns: FPMAJ Drug Pricing Chief
June 12, 2023

ORGANIZATION

EFPIA Japan, Patient Groups Call for Stronger Health Literacy, PPI
December 22, 2025
JPMA Exec Renews Call for Simpler Drug Pricing System
December 19, 2025
JGA to Create “Stable Supply Network” Membership to Expand Ramp-Up Scheme
December 18, 2025
Pharma Groups Reiterate “No” to Broader CEA Use, Huge-Seller and Spillover Rules: Joint Statement
December 17, 2025
Japan Medical Societies Recommend RSV Vaccination for Older Adults
December 15, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests

By Takashi Ebisawa

The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…

COMMENTARY

Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise

By Koji Shimomura

Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…